David Sable (Wharton Magazine)
On the subject of the upcoming AVANDIA advisory committee - posts collected by Matthew Herper at Forbes:
The Hidden Agenda Behind The FDA's New Avandia Hearings (Steve Nissen)
The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting
Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
Debunking Myths About Biotech Venture Capital
Bruce Booth (LifeSciVC)
Zillions of Biotech Conferences Want You. Which Should You Attend?
Luke Timmerman (Xconomy)
New Legislation Seeks Creation of Provisional Approval Pathway for New Drugs
Alec Gaffney (RegulatoryFocus)
So many terrible ideas in this law's current form I don't know where to start...
FDA Rethinking Personalized Drug Trials
David Pittman (MedpageToday)